---
title: "RBC Capital Remains a Buy on Doximity (DOCS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286629523.md"
description: "RBC Capital has maintained a Buy rating on Doximity (DOCS) with a price target of $28.00, while shares closed at $18.01. Analyst Ryan Halsted has an average return of -11.2% and a success rate of 18.42%. Doximity also received a Buy from Leerink Partners, but Goldman Sachs assigned a Hold rating."
datetime: "2026-05-16T01:50:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286629523.md)
  - [en](https://longbridge.com/en/news/286629523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286629523.md)
---

# RBC Capital Remains a Buy on Doximity (DOCS)

In a report released on May 14, Ryan Halsted from RBC Capital maintained a Buy rating on Doximity, with a price target of $28.00. The company’s shares closed yesterday at $18.01.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Halsted covers the Healthcare sector, focusing on stocks such as IQVIA Holdings, Medpace Holdings, and Sotera Health. According to TipRanks, Halsted has an average return of \-11.2% and a 18.42% success rate on recommended stocks.

In addition to RBC Capital, Doximity also received a Buy from Leerink Partners’s Michael Cherny in a report issued yesterday. However, on the same day, Goldman Sachs assigned a Hold rating to Doximity (NYSE: DOCS).

### Related Stocks

- [DOCS.US](https://longbridge.com/en/quote/DOCS.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [IQV.US](https://longbridge.com/en/quote/IQV.US.md)
- [MEDP.US](https://longbridge.com/en/quote/MEDP.US.md)
- [SHC.US](https://longbridge.com/en/quote/SHC.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [Truist Financial Reiterates "Hold" Rating for Doximity (NYSE:DOCS)](https://longbridge.com/en/news/286436506.md)
- [Doximity (NYSE:DOCS) Sets New 52-Week Low After Insider Selling](https://longbridge.com/en/news/286429497.md)
- [Doximity, Inc. (NYSE:DOCS) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/286529492.md)
- [Doximity Flags Pharma Ad Market Weakness](https://longbridge.com/en/news/286444124.md)
- [Doximity (DOCS) Q1 Earnings: What To Expect](https://longbridge.com/en/news/286027626.md)